Allemannsdata Wiki
Manual search

EXACT THERAPEUTICS AS

Organization number 998317487 · Aksjeselskap

Programmatic access to company data (JSON)

Source: Firmafakta. Data read and page generated 2026-09-18T10:28:05Z. HTML cache: no-store (TTL 0 seconds). Default TTL for Firmafakta JSON/API responses: 60 seconds.

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:
998317487
navn:
EXACT THERAPEUTICS AS
organisasjonsform:
kode:
AS
beskrivelse:
Aksjeselskap
naeringskode1:
kode:
72.100
beskrivelse:
Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk
antallAnsatte:
12
hjemmeside:
not reported by source
epostadresse:
not reported by source
telefon:
not reported by source
forretningsadresse:
adresse:
Sognsveien 72
poststed:
OSLO
postnummer:
0855
kommune:
OSLO
stiftelsesdato:
2012-04-12
registreringsdatoenhetsregisteret:
2012-04-30
aktivitet:
Legemiddelutvikling.
vedtektsfestetFormaal:
Legemiddelutvikling og andre tjenester og produkter som naturlig, faller sammen med dette, herunder å delta i andre selskaper med, lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre, seg interessert i andre foretagender samt kjøp, salg og utleie av fast, eiendom.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

Regnskapsfører

Revisor

Styre

Owners

Source: Firmafakta shareholder dataset.

Showing top 50 of 271 shareholders by holding size. Raise 'limit' (max 1000) for more.

  1. INVESTINOR DIREKTE AS – 9.65 % (3096083 shares, share class: NO0010852213)
  2. KVÅLE AS – 9.43 % (3024270 shares, share class: NO0010852213)
  3. PAACS INVEST AS – 8.42 % (2699842 shares, share class: NO0010852213)
  4. BREKKE HOLDING AS – 7.66 % (2458961 shares, share class: NO0010852213)
  5. CANICA AS – 7.08 % (2271000 shares, share class: NO0010852213)
  6. ANDREW JOHN HEALEY – 6.87 % (2205385 shares, share class: NO0010852213)
  7. PER CHRISTIAN SONTUM – 5.99 % (1922105 shares, share class: NO0010852213)
  8. OPTIMUSPISTOR AS – 4.97 % (1594750 shares, share class: NO0010852213)
  9. HELENE SUNDT AS – 4.43 % (1422666 shares, share class: NO0010852213)
  10. VERDIPAPIRFONDET NORDEA AVKASTNING – 3.88 % (1244999 shares, share class: NO0010852213)
  11. KVANTIA AS – 3.63 % (1165568 shares, share class: NO0010852213)
  12. CGS HOLDING AS – 2.78 % (890500 shares, share class: NO0010852213)
  13. P53 INVEST AS – 2.26 % (726500 shares, share class: NO0010852213)
  14. VERDIPAPIRFONDET DANSKE INVEST NORGE VEKST – 1.91 % (611583 shares, share class: NO0010852213)
  15. PORTIA AS – 1.8 % (576750 shares, share class: NO0010852213)
  16. T.D. VEEN AS – 1.59 % (509500 shares, share class: NO0010852213)
  17. VIRKELYST AS – 1.26 % (405288 shares, share class: NO0010852213)
  18. WILLIAM MARTIN CASTELL – 1.08 % (346664 shares, share class: NO0010852213)
  19. DET NORSKE EIENDOMSCOMPAGNIE AS – 0.91 % (291839 shares, share class: NO0010852213)
  20. SUNDT AS – 0.91 % (291666 shares, share class: NO0010852213)
  21. TROND MOHN FORSKNINGSSTIFTELSE – 0.9 % (288500 shares, share class: NO0010852213)
  22. FIKKAN PHARMA AS – 0.88 % (281892 shares, share class: NO0010852213)
  23. DNB BANK ASA – 0.8 % (258111 shares, share class: NO0010852213)
  24. WEINBERG INVEST AS – 0.66 % (210500 shares, share class: NO0010852213)
  25. TRI-LI HOLDING AS – 0.62 % (200250 shares, share class: NO0010852213)
  26. PEGUS AS – 0.61 % (196250 shares, share class: NO0010852213)
  27. GRATIUS AS – 0.59 % (187750 shares, share class: NO0010852213)
  28. SCIENCE INVEST AS – 0.56 % (179250 shares, share class: NO0010852213)
  29. UBIQUITY AS – 0.42 % (134000 shares, share class: NO0010852213)
  30. TRK GROUP AS – 0.4 % (128250 shares, share class: NO0010852213)
  31. JAKOB HATTELAND HOLDING AS – 0.39 % (123875 shares, share class: NO0010852213)
  32. CAABY AS – 0.38 % (123440 shares, share class: NO0010852213)
  33. J.P. MORGAN SECURITIES LLC – 0.38 % (121898 shares, share class: NO0010852213)
  34. MARTE OTTESEN – 0.27 % (86000 shares, share class: NO0010852213)
  35. KARL ØYVIND TRANDEM – 0.27 % (85500 shares, share class: NO0010852213)
  36. MICHELET CONSULT AS – 0.25 % (79500 shares, share class: NO0010852213)
  37. ANN KRISTIN LINDBAK – 0.24 % (77500 shares, share class: NO0010852213)
  38. BMH INVEST AS – 0.24 % (77000 shares, share class: NO0010852213)
  39. STIG HEMSTAD – 0.24 % (75884 shares, share class: NO0010852213)
  40. JAKOB IQBAL – 0.21 % (66250 shares, share class: NO0010852213)
  41. EWS STIFTELSEN – 0.18 % (59267 shares, share class: NO0010852213)
  42. BASEN KAPITAL AS – 0.18 % (58333 shares, share class: NO0010852213)
  43. ONGSJØFJELL AS – 0.18 % (57750 shares, share class: NO0010852213)
  44. NEMETH FINANS AS – 0.16 % (52500 shares, share class: NO0010852213)
  45. JESEM AS – 0.16 % (51000 shares, share class: NO0010852213)
  46. WESTHAWK AS – 0.16 % (50000 shares, share class: NO0010852213)
  47. ÅSE RAKNES – 0.16 % (50000 shares, share class: NO0010852213)
  48. IDA KJERSEM SOLHJELL – 0.14 % (44522 shares, share class: NO0010852213)
  49. DAG MAGNAR EVJE – 0.14 % (43455 shares, share class: NO0010852213)
  50. ØYSTEIN HEGGELUND DAHL – 0.13 % (43001 shares, share class: NO0010852213)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (1)

1 results

  1. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    998317487
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    virkemiddelkategori:
    Klynger og nettverk
    underkategori:
    Klyngeprogrammet
    innvilget_belop:
    500000
    innvilget_dato:
    04.12.17
    beslutningsenhet:
    IN Oslo og Akershus og Østfold
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk
    type_finansiering:
    Tilskudd

EU-tildelinger (0)

No registered grants.

Forskningsrådet (8)

8 results

  1. id:
    74078
    prosjektnummer:
    340905
    prosjekttittel:
    Enhancing immune response in solid tumours with Acoustic Cluster Therapy (ACT®)
    prosjektstart:
    2023
    prosjektslutt:
    2027
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Onkologi
    tildelt_belop:
    2.99
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  2. id:
    77211
    prosjektnummer:
    346691
    prosjekttittel:
    Acoustic Cluster Therapy (ACT®) to improve immunotherapy and gene therapy for cancer treatment and brain diseases
    prosjektstart:
    2023
    prosjektslutt:
    2027
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Nanoteknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Frittstående prosjekter
    aktivitet:
    Andre frittstående prosjekter
  3. id:
    73301
    prosjektnummer:
    336946
    prosjekttittel:
    Enhancing immune response in solid tumours with Acoustic Cluster Therapy (ACT®)
    prosjektstart:
    2022
    prosjektslutt:
    2026
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Onkologi
    tildelt_belop:
    0.0
    virkemiddel:
    Felleskostnader
    aktivitet:
    Utlysningsaktiviteter
  4. id:
    65610
    prosjektnummer:
    323966
    prosjekttittel:
    Ultrasound Transducer for Acoustic Cluster Therapy
    prosjektstart:
    2021
    prosjektslutt:
    2022
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Onkologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  5. id:
    42533
    prosjektnummer:
    269818
    prosjekttittel:
    Akustisk Cluster Terapi for bukspyttkjertelkreft
    prosjektstart:
    2017
    prosjektslutt:
    2021
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Bioteknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  6. id:
    42854
    prosjektnummer:
    270643
    prosjekttittel:
    GMP Manufacturing of ACT drug product
    prosjektstart:
    2017
    prosjektslutt:
    2017
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Tverr/flerfaglig innen teknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  7. id:
    37139
    prosjektnummer:
    256876
    prosjekttittel:
    Acoustic Cluster Therapy for Cancer Treatment
    prosjektstart:
    2016
    prosjektslutt:
    2020
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Medisinsk teknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  8. id:
    1590
    prosjektnummer:
    228604
    prosjekttittel:
    A Technology Platform for Localized Delivery of Medicinal Drugs
    prosjektstart:
    2013
    prosjektslutt:
    2017
    prosjektansvarlig_navn:
    EXACT THERAPEUTICS AS
    organisasjonsnummer:
    998317487
    sokt_belop:
    Medisinsk teknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer

SkatteFUNN (8)

8 results

  1. id:
    45316
    innsendt_dato:
    2017-08-29
    prosjektnummer:
    277881
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    A Technology Platform for Localized Delivery of Medicinal Drugs
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2017-09-14
    prosjekt_fra_ar:
    2017
    prosjekt_til_ar:
    2020
    sammendrag:
    not reported by source
  2. id:
    30570
    innsendt_dato:
    2013-08-20
    prosjektnummer:
    232353
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    A Technology Platform for Localized Delivery of Medicinal Drugs
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2013-09-11
    prosjekt_fra_ar:
    2013
    prosjekt_til_ar:
    2015
    sammendrag:
    not reported by source
  3. id:
    39195
    innsendt_dato:
    2016-03-09
    prosjektnummer:
    259833
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    A Technology Platform for Localized Delivery of Medicinal Drugs
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2016-03-14
    prosjekt_fra_ar:
    2016
    prosjekt_til_ar:
    2017
    sammendrag:
    not reported by source
  4. id:
    69732
    innsendt_dato:
    2023-09-21
    prosjektnummer:
    349661
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    Enabling precision medicine with a platform for targeted ultrasound mediated drug delivery
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2023-12-19
    prosjekt_fra_ar:
    2023
    prosjekt_til_ar:
    2026
    sammendrag:
    EXACT Therapeutics AS is a Norwegian biotech company evaluating the potential of ultrasound mediated therapeutic enhancement (sonoporation) based on its proprietary Acoustic Cluster Therapy (ACT) formulation, initially in the treatment of selected cancers. Research and development of ACT® has been conducted in collaboration with leading institutions in oncology research and development including the Institute for Cancer Research ("ICR")/Royal Marsden Hospital in London, UK, the Translational Genomics Research Institute in Arizona, US ("TGen"), Norwegian University of Science and Technology in Trondheim, Norway ("NTNU"). The Company has a long history of collaboration with GE Healthcare including manufacturing of the ACT® formulation and ultrasound probe development. ACT® is supported by strong and broad preclinical data demonstrating therapeutic enhancement in multiple oncology models, whilst the first-in-man phase I ACTIVATE study is ongoing at amongst others the Royal Marsden Hospital in London. This study is evaluating the potential of ACT combined with standard of care chemotherapy in the treatment of patients with advanced colorectal cancer. Based on further successful development, it is anticipated that application of ACT® sonoporation in combination of chemotherapy will enhance the impact of the chemotherapy on tumour regression thereby increasing the probability of successful surgical resection. The ACT® platform has the potential to be disease and drug agnostic and is being developed for use with clinically approved diagnostic ultrasound scanners that are commonly found in hospitals and clinics worldwide. Beyond oncology the company is also investigating the potential of ACT in other disease areas such as neurological conditions.
  5. id:
    61287
    innsendt_dato:
    2020-11-06
    prosjektnummer:
    321910
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    Clinical Development of Acoustic Cluster Therapy within Oncology
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2020-12-01
    prosjekt_fra_ar:
    2020
    prosjekt_til_ar:
    2023
    sammendrag:
    EXACT Therapeutics AS is an Anglo-Norwegian biotech company evaluating the potential of ultrasound mediated therapeutic enhancement (sonoporation) based on its proprietary Acoustic Cluster Therapy (ACT) formulation, initially in the treatment of selected cancers. Research and development of ACT® has been conducted in collaboration with leading institutions in oncology research and development including the Institute for Cancer Research ("ICR")/Royal Marsden Hospital in London, UK, the Translational Genomics Research Institute in Arizona, US ("TGen"), Norwegian University of Science and Technology in Trondheim, Norway ("NTNU"). The Company has a long history of collaboration with GE Healthcare including manufacturing of the ACT® formulation and ultrasound probe development. ACT® is supported by strong and broad preclinical data demonstrating therapeutic enhancement in multiple oncology models, whilst the first-in-man phase I ACTIVATE study has been initiated at the Royal Marsden Hospital in London in Sept 2019. This study is evaluating the potential of ACT combined with standard of care chemotherapy in the treatment of patients with advanced colorectal cancer. Based on further successful development, it is anticipated that application of ACT® sonoporation in combination of chemotherapy will enhance the impact of the chemotherapy on tumour regression thereby increasing the probability of successful surgical resection. The ACT® platform has the potential to be disease and drug agnostic and is being developed for use with clinically approved diagnostic ultrasound scanners that are commonly found in hospitals and clinics worldwide. The aim of the current project is to demonstrate the clinical utility of ACT in combination with chemotherapy for treatment of various solid tumor diseases, to a stage where regulatory approval for a first indication can be sought.
  6. id:
    61286
    innsendt_dato:
    2020-11-06
    prosjektnummer:
    321909
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    Ultrasound Transducer for Acoustic Cluster Therapy
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2020-11-16
    prosjekt_fra_ar:
    2020
    prosjekt_til_ar:
    2022
    sammendrag:
    Acoustic Cluster Therapy (ACT) is a novel approach to targeted therapeutic enhancement comprising a unique microbubble-microdroplet cluster formulation that is activated by the application of regular diagnostic ultrasound. The procedure consists of a two-step process, firstly intravenous administration of the micro-bubble-microdroplet formulation followed by the application of ultrasound to enhance therapeutic delivery of the co-administered pharmaceutical product. In this project we will focus on developing the next generation ultrasound technology that will allow the ability to perform ACT on a vast array of indications, treating them in 3D whilst using ultrasound consoles already available in clinical facilities world-wide.
  7. id:
    28277
    innsendt_dato:
    2012-08-21
    prosjektnummer:
    223227
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    Phase shift drug delivery technology: construction of product characterisation equipment
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2012-10-29
    prosjekt_fra_ar:
    2012
    prosjekt_til_ar:
    2012
    sammendrag:
    not reported by source
  8. id:
    59401
    innsendt_dato:
    2020-08-28
    prosjektnummer:
    318671
    bedriftsnavn:
    EXACT THERAPEUTICS AS
    prosjekttittel:
    A Technology Platform for Targeted Delivery of Medicinal Products
    organisasjonsnummer:
    998317487
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    NEI
    soknad_avslatt:
    NEI
    vedtaksdato:
    not reported by source
    prosjekt_fra_ar:
    2020
    prosjekt_til_ar:
    2023
    sammendrag:
    EXACT Therapeutics AS is an Anglo-Norwegian biotech company evaluating the potential of ultrasound mediated therapeutic enhancement (sonoporation) based on its proprietary Acoustic Cluster Therapy (ACT) formulation, initially in the treatment of selected cancers. Research and development of ACT® has been conducted in collaboration with leading institutions in oncology research and development including the Institute for Cancer Research ("ICR")/Royal Marsden Hospital in London, UK, the Translational Genomics Research Institute in Arizona, US ("TGen"), Norwegian University of Science and Technology in Trondheim, Norway ("NTNU"). The Company has a long history of collaboration with GE Healthcare including manufacturing of the ACT® formulation and ultrasound probe development. ACT® is supported by strong and broad preclinical data demonstrating therapeutic enhancement in multiple oncology models, whilst the first-in-man phase I ACTIVATE study has been initiated at the Royal Marsden Hospital in London in Sept 2019. This study is evaluating the potential of ACT combined with standard of care chemotherapy in the treatment of patients with advanced colorectal cancer. Based on further successful development, it is anticipated that application of ACT® sonoporation in combination of chemotherapy will enhance the impact of the chemotherapy on tumour regression thereby increasing the probability of successful surgical resection. The ACT® platform has the potential to be disease and drug agnostic and is being developed for use with clinically approved diagnostic ultrasound scanners that are commonly found in hospitals and clinics worldwide. Beyond oncology the company is also investigating the potential of ACT in other disease areas such as infectious diseases and neurological conditions.

Subunits

Open positions

count:
0
stillinger:

No results.

Related lookups

How an AI agent should use this page

Ground rule: Navigate with HTML GET links to keep explanations and relationships. Use the page's JSON alternative only when concrete values must be extracted, compared or computed.

How to use the company page

  1. Use the organization number as the stable key.
  2. Distinguish between the company's own facts, roles, owners, holdings and grants.
  3. Follow person and company links to explore the graph; do not assume relations that are not explicitly registered.

Related services

Time: Ownership, roles and status can change. State the source and retrieval time with factual claims.

AI agent? Read the complete navigation and programming guide.